PAVmed (PAVM) –
-
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
-
Lucid Diagnostics Inc (LUCD) Provides Business Update, Reports Prelim Q4
-
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
-
Form 10-K PAVmed Inc. For: Dec 31
-
Lucid Diagnostics Inc (LUCD) Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
-
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
-
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
-
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
-
Form 8-K PAVmed Inc. For: Mar 13
-
Form 8-K PAVmed Inc. For: Mar 12
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
-
Form 8-K PAVmed Inc. For: Mar 07
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: Sparks Ronald M
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: Baxter Timothy E
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: White Debra
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: Glennon Michael J
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: Harvey Joan B
-
Form 4 PAVmed Inc. For: Feb 22 Filed by: Cox James L
-
Lucid Diagnostics Inc (LUCD) Provides Update Regarding World Trade Center Health Program
-
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
-
Form 8-K PAVmed Inc. For: Feb 15
-
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
-
Form SC 13G PAVmed Inc. Filed by: Ayrton Capital LLC
-
Form 8-K PAVmed Inc. For: Feb 09
-
Lucid Diagnostics Inc (LUCD) Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
-
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
-
Form S-8 PAVmed Inc.
-
Form S-8 PAVmed Inc.
-
Form 8-K PAVmed Inc. For: Jan 26
-
Form 8-K PAVmed Inc. For: Jan 05
-
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
-
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
-
Form 8-K PAVmed Inc. For: Dec 05
-
PAVmed (PAVM) Announces Dividend of Lucid Diagnostics (LUCD) Common Stock and Reverse Stock Split
-
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
-
Lucid Diagnostics Inc (LUCD) Strengthens and Expands Market Access and Direct Contracting Efforts
-
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
-
Form 8-K PAVmed Inc. For: Nov 14
-
PAVmed Inc. (PAVM) Tops Q3 EPS by 5c
-
PAVmed Provides Business Update and Third Quarter Financial Results
-
Lucid Diagnostics Inc (LUCD) Reports Q3, Provides Business Update
-
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
-
Form 10-Q PAVmed Inc. For: Sep 30
-
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
-
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
-
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
-
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
Back to PAVM Stock Lookup
